Carl Icahn Plans to Replace Genzyme’s CEO and Three Directors
| May 8th, 2010 | ||
| Carl Icahn issued a proxy statement announcing that he is planning to replace biotech company Genzyme Corporation’s CEO Henri Termeer and three other members from its board of ten directors. Mr. Icahn also reiterated that Genzyme’s flawed manufacturing system needs adjustments. Genzyme officials challenged Mr. Icahn’s selection of Alexander Denner and Richard Mulligan for replacement, arguing that these two board members also serve on the board of Biogen Idec, a biotech company that might want to access confidential information about Genzyme. Mr. Icahn dismissed this argument in the proxy statement. | ||
See Source | ||
For Detailed Investor Profiles on these Investors, click below: |
Icahn Associates (Carl Icahn) |
Related People: Alexander J. Denner;
Related Entities: High River Limited Partnership;
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles
Add a Comment |
More Recent Headlines
Pershing Square’s Bill Ackman Proposes Public Database to Prevent Fraud |
April a Good Month for Hedge Fund Returns |
Lawyers for Galleon’s Raj Rajaratnam Fighting Wiretaps |
Deutsche Telekom Discussing Partnership with Harbinger Capital Partners |
Asian Development Bank launches $9 Billion Plan for Solar Energy in Asia |
Feds Charge SpongeTech CEO with Obstruction of Justice in Pump and Dump Stock Investigation |
Caxton veteran’s Redux Research launches Matrix Redux hedge fund |
Another Senior Management Departure at Citadel Investment Group |
Regulatory Environment makes US more attractive to Hedge Funds than Europe |
Jabre Capital Partners’ Founder Sees Momentum in Depressed Sectors |
